Russia finalizes rules for granting preference to domestic drugs in public procurements
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025.
The most important novelty is that the “second extra” mechanism will be extended to vital drugs, reports The Pharma Letter’s local correspondent.
The "second extra" mechanism means if at least one supplier of a drug that is produced in Russia or the countries of the Eurasian Economic Union (EEU) in a full cycle, applies for the auction, then the remaining applications are rejected automatically. Such a rule should motivate manufacturers to deepen the localization of drugs in Russia instead of using foreign raw materials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze